Stock Watch: Pfizer Gets Back To Business As Usual
New Launches Come Into Focus As COVID-19 Vaccine Sales Recede
Executive Summary
Sales Of Pfizer’s pandemic products decline as other vaccines are scheduled for a second-half launch but the road back to 2022’s all-time high in annual revenues will not be easy.
You may also be interested in...
Stock Watch: Pfizer Pushed And Pulled By Pandemic Products
With Pfizer expecting significant pandemic-related sales out to at least 2026, the difficulty forecasting those sales and inventory work-down resulted in stock price volatility.
Stock Watch: Biopharma Caught In US Government Anti-Bundling Drive
Medicare price renegotiation and the FTC’s scrutiny of biopharma acquisitions have suppressed sector stock prices. But the sector may not be the actual target.
Stock Watch: Pharmaceutical Succession
GLP-1 agonists are creating a stir in obesity management and could possibly prevent non-alcoholic fatty liver disease, with implications for developers of NAFLD treatments. Similarly, another preventative intervention might succeed the treatments for Alzheimer’s disease.